Prof. Giorgi Pkhakadze
Experimental Drug Shows 96% Viral Suppression in Hepatitis B Clinical Trial
Clinical trial shows experimental drug bepirovirsen achieves 96% viral suppression when combined with standard hepatitis B therapy. Phase III trials…
World’s Largest Longevity Competition Targets Age Reversal Breakthroughs
The XPRIZE Healthspan competition offers $101 million in prizes for age reversal breakthroughs targeting cognitive, muscle, and immune function. Dr.…
Lab-grown brain organoids reveal how to reverse ‘irreversible’ nerve damage
Cambridge researchers used lab-grown brain organoids to discover that human neurons lose regenerative capacity during development, but thyroid hormone therapy…
Phase 3 Trial of Bepirovirsen Shows Promise for Chronic Hepatitis B Treatment
Phase 3 clinical trial results for bepirovirsen, a novel antisense oligonucleotide therapy for chronic hepatitis B, published in The New…
Weight Loss Expert Raises Safety Concerns Over Unregulated GLP-1 ‘Microdoses’
Weight-loss specialist warns about unregulated GLP-1 microdosing trend lacking clinical trial evidence. Long-term safety effects remain unknown for reduced-dose formulations.
Non-surgical vision correction technique could challenge LASIK dominance
Researchers have developed a breakthrough vision correction technique using platinum contact lenses and electrical pulses that could reshape the cornea…
Moldova probation centres identify 136 people with opioid disorders through innovative screening programme
Research across 10 Moldovan probation centres identified 136 people with opioid use disorder among 900 participants, with 97% treatment retention…
WOAH Calls for Global Phase-Out of Lead Hunting Ammunition to Protect Wildlife and Human Health
The World Organisation for Animal Health calls for global elimination of lead hunting ammunition, citing 10-20 million annual bird deaths…